Maigaban Jagora: Shugaban Kasuwancin Biotech yana ci gaba da matsayin saboda sabon ci gaba

Anonim

Maigaban Jagora: Shugaban Kasuwancin Biotech yana ci gaba da matsayin saboda sabon ci gaba 11513_1

American Vertex Pharmaceuticals (nasdaq: VRTX) yana ɗaya daga cikin mafi saurin girma manyan kamfanonin Biote. Yawan mawuyacin karuwa na 2025 - 10% a shekara. Kamfanin ya kware a ci gaba a fagen cututtukan kwayoyin halitta kuma hakika ne kawai wanda yake samar da magunguna daga fibrosis gabobi). Yana ba da kyakkyawan fa'ida, kwarara tsabar kuɗi mai aminci da kuma hanyoyin sababbin ayyukan.

Yanzu kamfanin yana ƙoƙarin haɓaka layin magunguna kuma yana zuwa ga sauran kyawawan abubuwan da aka yi, alal misali, wata mummunar matsala.

A karshen shekarar 2019, hukumar tarayya ta Amurka ga Kayayyakin Magunguna da Kulawa da aka amince da sabon hadewar kwayoyi daga fibrosis (Trikaifta / Kafrasio). Wani sabon magani zai iya zama babban direban girma na tallace-tallace. Ya kamata ya ba da izinin maye gurbin shirye-shiryen tsofaffin kamfanin da wannan fadada samfurin marasa lafiya a kan sama da 1/3 (saboda yawan masu laifi).

Maigaban Jagora: Shugaban Kasuwancin Biotech yana ci gaba da matsayin saboda sabon ci gaba 11513_2
Masu gabatar da yarjejeniya

Sakamakon binciken na 4 na kashi 2020 na masu jin takaici, duk da alamomin ban sha'awa. Girman tallace-tallace na cin nasara tare, amma ɗan ɓoye na EPs ya haifar da mummunar haɓakawa saboda yawan tsammanin saboda yawan tsammanin. Ana iya maimaita wannan a nan gaba.

A hannun jari sun nemi fa'ida da rikicewa da kasuwar, tunda a watan Oktoba a bara cewa kamfanin ya dakatar da miyagun ƙwayoyi daga kasawar alfa-1-antitripsein. Koyaya, Vertex tana haɓaka wani magani daban-daban daga cutar, wanda ake sa ran bayanan asibiti a farkon rabin 2021, wanda zai iya haifar da juyawa.

Maigaban Jagora: Shugaban Kasuwancin Biotech yana ci gaba da matsayin saboda sabon ci gaba 11513_3

Idan aka kwatanta da samfurin ƙungiya guda (ƙwararren ƙwararru na zamani suna ɗimbin yawa), vertix yana alfahari da ajiyar kuɗi mai yawa (sau biyu na matakin bashin kamfanin). Roe Vertex shine 37%, wanda ya fi sau biyar da sau biyar da matsakaici. Daga yanayin tabbatar da alamun alamun, yana da kyau a nuna alamar low p / FCF akan samfurin (19 da 29, bi da bi), wanda ke nufin alamar farashi mai kyau tare da kyakkyawan kamfani na kamfani. A cikin sauran manufofin alamomi, kamfanin ya yi ciniki a fannin matsakaita samfurori.

Maigaban Jagora: Shugaban Kasuwancin Biotech yana ci gaba da matsayin saboda sabon ci gaba 11513_4
Maigaban Jagora: Shugaban Kasuwancin Biotech yana ci gaba da matsayin saboda sabon ci gaba 11513_5

Mazaunin Evgeny Shatov, gwamnonin gwamnoni "

Karanta abubuwan asali na asali akan: zuba jari.com

Kara karantawa